Big Bavarian Nordic shareholder on pivotal projects: "We're in a completely unique position"

Danish pensions firm ATP, which has a large stake in Bavarian Nordic, remains confident in the Danish biotech firm's ability to manage two crucial projects.

Photo: Bavarian Nordic / PR

Bavarian Nordic is in the unique position to potentially catapult its tried-and-tested biotech foundation into a league of its own, says the shareholder ATP.

"Bavarian Nordic is a super interesting place. Here we have another Danish company that will be able to generate big profits every year after it has completed two phase III studies. At the same time, we have two potential upsides in the shape of its RSV and Covid-19 vaccine projects," says Claus Berner Møller, vice president of Danish equities at ATP, which owns a 10-percent stake in Bavarian Nordic equating to at least DKK 1.8bn (USD 274m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs